Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.35 +2.19%

+$0.43 today

Market cap
$185.61M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 1.58M

Average 0.22M

PRE Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Prenetics Global LimitedNASDAQ: PRE

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns negative

Q1 FY2026 financing cash flow was -$13.27M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $24.27M. Over 3 fiscal years it compounded at -36.0% a year.

Context

  • Financing cash flow amounted to 40.6% of revenue in FY2025, up 29.7 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near -$13.27M or moves back toward the trailing-twelve-month quarterly average of $6.07M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.27M-135.3% QoQ
Last fiscal yearDec 2025
$37.54M+1223.0% YoY
LTMMar 2026
$24.27M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1223.0%——
3-year CAGR-36.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
37.54M USD
Year-over-year change
+1223.0%
4-year CAGR
+6.4%

Financing Cash Flow vs competitors

How PRE compares with its peers on the latest reported figures

  • PRE's LTM Mar 2026 financing cash flow of $24.27M is the 5th largest of the 11 companies compared; the peer median is $20.24M.
  • Financing cash flow amounts to 21.3% of revenue for PRE, versus a peer median of 87.9%.
PRE Competitors Peer median
Financing Cash Flow for PRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$89.31M +520.7%-5.8%258.5%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$63.46M +42.6%+31.7%141.4%
PROFProfound Medical Corp.LTM Mar 2026$42.24M +23.6%+81.2%223.8%
CDXSCodexis, Inc.LTM Mar 2026$26.83M -17.0%—34.4%
PREPrenetics Global LimitedLTM Mar 2026$24.27M —-36.0%21.3%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$24.21M -50.6%-7.8%1242.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$22.27M +481.2%-83.6%19.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$16.27M +62.5%-16.5%549.9%
STIMNeuronetics, Inc.LTM Mar 2026$11.3M -7.2%+457.4%7.4%
ATLNAtlantic International Corp.LTM Dec 2025$3.87M -28.2%—0.9%
MXCTMaxCyte, Inc.LTM Mar 2026$278K -84.0%-39.0%0.9%
Peer median (excluding PRE) $20.24M+8.2%-6.8%87.9%

Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.02M)(190.45M)(64.78M)(49.81M)(52.7M)
Depreciation & Amortization7.35M7.54M7.79M5.93M3.78M
Deferred Income Tax3.73M7.15M(385.84K)(7.87M)0
Stock-Based Compensation22.49M31.58M10.59M11.98M0
Change in Working Capital(6.59M)(33.76M)24.21M1.97M6.62M
Accounts Receivables(24.06M)6.97M37.63M(428K)(529K)
Inventory(2.33M)1.26M(1.73M)1.32M(3.38M)
Accounts Payables(3.46M)(2.63M)(5.62M)(4.68M)4.91M
Other Working Capital23.26M(39.36M)(6.08M)5.75M5.62M
Other Non-Cash Items160.45M192.46M8.8M8.93M20.48M
Operating Cash Flow13.42M14.51M(13.76M)(28.87M)(21.81M)
Capital Expenditures(11.41M)(6.34M)(911.81K)(1.07M)(208K)
Acquisitions (Net)0(3.42M)021.65M37.78M
Purchases of Investments(10M)(39.92M)(26M)(129K)(20M)
Sales of Investments03M19.92M16M0
Other Investing Activities(3.47M)531.99K(76.52M)2.02M1,000K
Investing Cash Flow(22.02M)(46.14M)(82.95M)38.54M(35.79M)
Debt Repayment(1.3M)(1.88M)(3.23M)(2.56M)40.15M
Common Stock Issued0116.86K2.17K02K
Common Stock Repurchased0(661.52K)(1.23M)(577K)0
Dividends Paid00000
Other Financing Activities4.65M145.86M(241.5K)(203K)(2.61M)
Financing Cash Flow29.32M143.32M(4.7M)(3.34M)37.54M
Effect of Forex Changes87.21K(317.47K)467.93K221K(65K)
Net Change in Cash20.8M111.37M(100.95M)6.55M(20.12M)
Free Cash Flow2M8.17M(14.68M)(29.94M)(22.02M)

Prenetics Global Limited

NASDAQ:PRE

Intrinsic Alpha fair value

Locked

Current Price

$10.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.